case_images: PMC10957750_01
case_images: PMC10957750_02
case_images: (A) Patient's continuous glucose monitoring (CGM) on insulin therapy. (B) Patient's CGM on semaglutide.
case_images: fendo-15-1294264-g001.jpg
case_images: PMC10957750_02_fendo-15-1294264-g001.jpg
case_images: f1
case_images: Dexcom Continuous Glucose Monitoring (CGM) was utilized to monitor the patient's status prior to ( Figure 1A ) and during ( Figure 1B ) the semaglutide trial. The coefficient of variation dropped from 34.3% to 33.4%, and on some days, it reduced further to 27% ( Figures 1A, B ).